Details of the Drug Combination

General Information of Drug Combination (ID: DCNWCV0)

Drug Combination Name
Indazole derivative 5 Valrubicin
Indication
Disease Entry Status REF
Melanoma Investigative [1]
Component Drugs Indazole derivative 5   DMM1I8R Valrubicin   DMOYJFK
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable
High-throughput Screening Result Testing Cell Line: SK-MEL-2
Zero Interaction Potency (ZIP) Score: 2.31
Bliss Independence Score: 2.19
Loewe Additivity Score: 1.06
LHighest Single Agent (HSA) Score: 0.59

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indazole derivative 5 Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
ABL T315I mutant (ABL T315I) TTZJTWA ABL1_HUMAN Inhibitor [5]
Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) TTIV39N BCR_HUMAN-ABL1_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------
Indication(s) of Valrubicin
Disease Entry ICD 11 Status REF
Bladder cancer 2C94 Approved [2]
In situ carcinoma N.A. Approved [3]
Urinary bladder cancer N.A. Approved [3]
Psoriasis vulgaris EA90 Phase 2 [4]
Valrubicin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN; TOP2B_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------
Valrubicin Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [7]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Anaplastic large cell lymphoma DCCEUHI SR Investigative [8]
Plasma cell myeloma DCOPYPK RPMI-8226 Investigative [8]
Invasive ductal carcinoma DCJEEJ2 T-47D Investigative [9]
Invasive ductal carcinoma DCPDFZD BT-549 Investigative [9]
Invasive ductal carcinoma DCYVMRB HS 578T Investigative [9]
Amelanotic melanoma DCKID3R MDA-MB-435 Investigative [1]
Cutaneous melanoma DCZLM7U SK-MEL-28 Investigative [1]
Lung adenocarcinoma DCVMIGK HOP-62 Investigative [1]
Melanoma DCFJY11 MALME-3M Investigative [1]
Ovarian serous cystadenocarcinoma DC96N5K SK-OV-3 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3 Valrubicin FDA Label
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
6 Metabolic activation of N-acylanthracyclines precedes their interaction with DNA topoisomerase II. NCI Monogr. 1987;(4):111-5.
7 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
8 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
9 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.